__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Indications:1
- KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
- In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist
KISQALI is not recommended to be used in combination with tamoxifen.
Support for KISQALI prescribers
These resources are designed to support healthcare professionals prescribing KISQALI. You can preview and download these tools, and if you would like to receive more information or printed copies of any materials, please contact a Novartis representative.
Patient information booklet: KISQALI + an aromatase inhibitor
This booklet provides your patients with information about what to expect from treatment with KISQALI + AI.
Patient information booklet: KISQALI + fulvestrant
This booklet provides your patients with information about what to expect from treatment with KISQALI + fulvestrant.
The KISQALI & Kardia package deal gives your patients access to technology to supplement cardiology clinical practice
The KISQALI & Kardia package deal is funded by Novartis Pharmaceuticals Ltd.
AI, aromatase inhibitor; GB, Great Britain; HCP, healthcare professional; HER2−, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; NI, Northern Ireland.
References
- KISQALI®️ (ribociclib) GB Summary of Product Characteristics.
- KISQALI®️ (ribociclib) NI Summary of Product Characteristics.